Semaglutide
STEP HFpEF DM
Novo Nordisk · Phase 3 · Completed · Enrollment 617
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg once weekly (OW) | 55 participants | 26 participants | 42 participants | n/r | 6 |
| Semaglutide placebo OW | 18 participants | 7 participants | 20 participants | n/r | 10 |
A count stays a count. This page does not turn a count into a percent.